Onishi Yasuhiro, Mise Koki, Kawakita Chieko, Uchida Haruhito A, Sugiyama Hitoshi, Sugawara Ryosuke, Yamaguchi Satoshi, Yoshida Michihiro, Mitsuhashi Toshiharu, Yamada Masao, Hirabayashi Jun, Wada Jun
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Am J Nephrol. 2022;53(1):10-20. doi: 10.1159/000520998. Epub 2021 Dec 29.
The pathogenic roles of aberrantly glycosylated IgA1 have been reported. However, it is unexplored whether the profiling of urinary glycans contributes to the diagnosis of IgAN.
We conducted a retrospective study enrolling 493 patients who underwent renal biopsy at Okayama University Hospital between December 2010 and September 2017. We performed lectin microarray in urine samples and investigated whether c-statistics of the reference standard diagnosis model employing hematuria, proteinuria, and serum IgA were improved by adding the urinary glycan intensity.
Among 45 lectins, 3 lectins showed a significant improvement of the models: Amaranthus caudatus lectin (ACA) with the difference of c-statistics 0.038 (95% CI: 0.019-0.058, p < 0.001), Agaricus bisporus lectin (ABA) 0.035 (95% CI: 0.015-0.055, p < 0.001), and Maackia amurensis lectin (MAH) 0.035 (95% CI: 0.015-0.054, p < 0.001). In 3 lectins, each signal plus reference standard showed good reclassification (category-free NRI and relative IDI) and good model fitting associated with the improvement of AIC and BIC. Stratified by eGFR, the discriminatory ability of ACA plus reference standard was maintained, suggesting the robust renal function-independent diagnostic performance of ACA. By decision curve analysis, there was a 3.45% net benefit by adding urinary glycan intensity of ACA to the reference standard at the predefined threshold probability of 40%.
The reduction of Gal(β1-3)GalNAc (T-antigen), Sia(α2-3)Gal(β1-3)GalNAc (Sialyl T), and Sia(α2-3)Gal(β1-3)Sia(α2-6)GalNAc (disialyl-T) was suggested by binding specificities of 3 lectins. C1GALT1 and COSMC were responsible for the biosynthesis of these glycans, and they were known to be downregulated in IgAN. The urinary glycan analysis by ACA is a useful and robust noninvasive strategy for the diagnosis of IgAN.
异常糖基化的IgA1的致病作用已有报道。然而,尿聚糖谱是否有助于IgA肾病的诊断尚不清楚。
我们进行了一项回顾性研究,纳入了2010年12月至2017年9月在冈山大学医院接受肾活检的493例患者。我们对尿样进行凝集素微阵列分析,并研究在采用血尿、蛋白尿和血清IgA的参考标准诊断模型中加入尿聚糖强度后,c统计量是否得到改善。
在45种凝集素中,有3种凝集素使模型有显著改善:尾穗苋凝集素(ACA),c统计量差异为0.038(95%CI:0.019 - 0.058,p < 0.001);双孢蘑菇凝集素(ABA),0.035(95%CI:0.015 - 0.055,p < 0.001);黑果腺肋花楸凝集素(MAH),0.035(95%CI:0.015 - 0.054,p < 0.001)。在这3种凝集素中,每个信号加参考标准均显示出良好的重新分类(无类别NRI和相对IDI)以及与AIC和BIC改善相关的良好模型拟合。按估算肾小球滤过率分层后,ACA加参考标准的鉴别能力得以维持,表明ACA具有强大的独立于肾功能的诊断性能。通过决策曲线分析,在预定义阈值概率为40%时,在参考标准中加入ACA的尿聚糖强度可带来3.45%的净效益。
3种凝集素的结合特异性提示Gal(β1 - 3)GalNAc(T抗原)、Sia(α2 - 3)Gal(β1 - 3)GalNAc(唾液酸T)和Sia(α2 - 3)Gal(β1 - 3)Sia(α2 - 6)GalNAc(双唾液酸T)减少。C1GALT1和COSMC负责这些聚糖的生物合成,且已知它们在IgA肾病中表达下调。通过ACA进行尿聚糖分析是一种用于诊断IgA肾病的有用且可靠的非侵入性策略。